Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Blood (2019) 134 (Supplement_1): 469.

https://doi.org/10.1182/blood-2019-123367

Published: 2019

Journal Articles

Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1

Jaspal Kaeda, PhD FRCPath, Simone Bonecker, Frauke Ringel, Michaela Schwarz, Bernd Dörken, Ilana Zalcberg, Philipp Le Coutre, MD

Blood (2015) 126 (23): 2784.

https://doi.org/10.1182/blood.V126.23.2784.2784

Published: 2015

Journal Articles

Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib.

Theo D. Kim, MD, Michaela Schwarz, MD, Karl-Anton Kreuzer, MD, Jaspal Kaeda, PhD, Kamran Movassaghi, MD, Peggy Grille, Peter Daniel, MD, PhD, Bernd Dörken, Philipp le Coutre

Blood (2010) 116 (21): 3418.

https://doi.org/10.1182/blood.V116.21.3418.3418

Published: 2010

Journal Articles

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Hugues de Lavallade, MD, Dragana Milojkovic, MD, Jamshid S. Khorashad, MD, Alistair Reid, PhD, Eduardo Olavarria, MD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1045.

https://doi.org/10.1182/blood.V110.11.1045.1045

Published: 2007

Journal Articles

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Dragana Milojkovic, MD, Simon Wagner, PhD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 323.

https://doi.org/10.1182/blood.V110.11.323.323

Published: 2007

Journal Articles

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

John M. Goldman, MD, Timothy Hughes, MD, Jerry Radich, MD, Susan Branford, PhD, Andreas Hochhaus, MD, Charlene So, PharmD, Insa Gathmann, MS, Elisabeth Wehrle, Jaspal Kaeda, PhD

Blood (2005) 106 (11): 163.

https://doi.org/10.1182/blood.V106.11.163.163

Published: 2005

Journal Articles

Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.

Sara Ghorashian, MD, Anna Babb, MD, Jamshid Khorasan, MD, Jaspal Kaeda, PhD, David Marin, MD, Jane Apperley, MD, PhD

Blood (2005) 106 (11): 2002.

https://doi.org/10.1182/blood.V106.11.2002.2002

Published: 2005

Journal Articles

Circulating Human Fetal Mesenchymal Stem Cells Support Ltc-Ic and Express a Cytokine Profile To Maintain Quiescence of Co-Circulating Hemopoietic Stem Cells Circulating Human Fetal Mesenchymal Stem Cells Support LTC-IC and Express a Cytokine Profile To Maintain Quiescence of Co-Circulating Hemopoietic Stem Cells.

Josu de la Fuente, MRCP, Jerry Chan, MBBS, Keelin O’Donoghue, MRCOG, Jaspal Kaeda, PhD, Sailesh Kumar, PhD, Nicholas M. Fisk, PhD, Irene A.G. Roberts, MD

Blood (2004) 104 (11): 2327.

https://doi.org/10.1182/blood.V104.11.2327.2327

Published: 2004

Journal Articles

Cyclin-C: Analysis of a Candidate Tumour Suppressor Genes on 6q15-q21 in Malignant Lymphoid Cell Lines and Lymphoid Acute Leukemias.

Paul B. Sinclair, PhD, Wayne Mitchell, PhD, Jaspal Kaeda, PhD, Letizia Foroni, MD, PhD

Blood (2004) 104 (11): 4332.

https://doi.org/10.1182/blood.V104.11.4332.4332

Published: 2004

NARROW

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1

Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib.

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.

Cyclin-C: Analysis of a Candidate Tumour Suppressor Genes on 6q15-q21 in Malignant Lymphoid Cell Lines and Lymphoid Acute Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only